Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Can Regenerative Medicine be the Cure for Cancer and Other Deadly Diseases?

Published: Thursday, June 19, 2014
Last Updated: Thursday, June 19, 2014
Bookmark and Share
Change in regulatory frameworks and standards are essential to expedite approval and release of innovative products.

Regenerative medicine has the potential to transform healthcare all over the world and usher human health into a new era of wellness. Currently, the majority of treatments for chronic and fatal diseases is palliative or to delay disease progression; in contrast, regenerative medicine is uniquely capable of altering the underlying disease mechanism and enabling cures.

New analysis from Frost & Sullivan’s Global Regenerative Medicine Market finds the increasing approval rates and clinical activity buzz point to regenerative medicine being an extremely attractive sector for investors. It covers the segments of cell therapy (CT), tissue engineering (TE), gene therapy (GT) and small molecules and biologics.

"Cell-based models are anticipated to speed-up the discovery of new molecules and biologics, the safety and toxicity testing of newly discovered drugs, and provide a solid understanding of underlying disease mechanisms,” said Frost & Sullivan Healthcare Senior Research Analyst Aiswariya Chidambaram. "As more pharma companies acquire profitable cell therapy companies or strategically invest in emerging cell and advanced therapy organizations, the consolidation wave is likely to rise higher in the industry."

A significant number of regenerative medicine products, particularly in CT and TE, are already commercially available. In 2012, the market witnessed the approval of as many as seven CT products by regulatory agencies worldwide, while only five such approvals were granted between 2009 and 2011, and none from 2002 to 2008.

However, despite the immense value of regenerative medicine, there is a lack of consensus and strategic interaction among members of the regenerative medicine community. There has to be greater assessment of activities at various federal agencies including government, industry, academia, and patient advocates, particularly in the U.S., to identify areas of redundancy and eventually bridge the gap.

To set up a more efficient coverage and a solid reimbursement framework, the various stakeholders have to streamline regulatory policies. They could achieve this by establishing a clear point of contact at the national level that will act as an interface among the Food and Drug Administration (FDA), Centers for Medicare & Medicaid Services (CMS), National Institutes of Health (NIH), National Center for Health Statistics (NCHS), other federal agencies and the private sector.

They will also do well to create fora/platforms to present recommendations for regulatory, reimbursement and research policies in order to foster product and clinical development.

"On the whole, governments all over the world are expected to implement legislative policies favouring the establishment of centres of excellence, manufacturing infrastructure, research networks and economic diversification to support the development of regenerative medicine," noted Chidambaram.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Changing Phase of Biomarkers
Discover the current scenario and changing business models of the biomarkers field.
Monday, April 13, 2015
Gene Expression Profiling Drives Personalized Medicine Worldwide
Large amounts of information generated by gene expression profiling will increase implementation of data management tools.
Tuesday, June 10, 2014
Personalized Medicine Drives Uptake of Next-generation Sequencing in Europe
Future of DNA sequencing will shift from a laboratory-based setup to point of care testing in the next 5 years.
Saturday, May 31, 2014
Next Generation Sequencing on the European Growth Path
Next Generation Sequencers have found their way into labs and the global biomedical research community. 2010 has seen a serious uptake of Next Generation Sequencing technology, and today it is perceived as an indispensable tool for researchers.
Wednesday, January 26, 2011
Scientific News
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Five New Genetic Variants Linked to Brain Cancer Identified
The biggest ever study of DNA from people with glioma – the most common form of brain cancer – has discovered five new genetic variants associated with the disease.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Fatty Liver Disease and Scarring Have Strong Genetic Component
Researchers say that hepatic fibrosis, which involves scarring of the liver that can result in dysfunction and, in severe cases, cirrhosis and cancer, may be as much a consequence of genetics as environmental factors.
Specific Variations in RNA Splicing Linked to Breast Cancer
Researchers have identified cellular changes that may play a role in converting normal breast cells into tumors. Targeting these changes could potentially lead to therapies for some forms of breast cancer.
Finding Links and Missing Genes
A catalogue of large-scale genetic changes around the world.
Scientists Test New Gene Therapy for Vision Loss from a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Gene Expression: A Snapshot of Stem Cell Development
New genes found that regulate development of stem cells.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
A Natural History of Neurons
Diverse mutations reveal lineage of brain cells.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos